ЎПКАНИНГ СУРУНКАЛИ ОБСТРУКТИВ КАСАЛЛИГИ ВА АРТЕРИАЛ ГИПЕРТЕНЗИЯДА БУЙРАКЛАР ДИСФУКЦИЯСИ (адабиётлар шархи)
##article.subject##:
ўпканинг сурункали обструктив касаллиги, артериал гипертензия, буйраклар дисфункцияси, сурункали буйрак касаллиги, коптокчалар филтирацияси тезлиги.##article.abstract##
Артериал гипертензия бутун дунёда, шу жумладан республикамизда хам кенг тарқалган хамда ўлимга олиб келувчи касалликлардан бири хисобланади. Ўпканинг сурункали обструктив касаллиги артериал гипертензия билан кечганда ва уларга буйрак дисфункцияси қўшилганда бундай коморбид холат беморлар умумий ахволига ўта салбий тасир кўрсатади хамда ўлим жараёнларини жадаллаштиради. Мазкур мақолада қайт этилган холатлар тўғрисида жахондаги етакчи тадқиқотчилар томонидан олиб борилган кузатувлар тахлил қилинган.
Библиографические ссылки
Драпкина О.М., Джиоева О.Н. Современные эхокардиографические критерии сердечной недостаточности с сохраненной фракцией выброса: не «Амурский медицинский журнал» №1 (31) 2021 С. 66-74.
Задионченко В. С., Ли В. В., Адашева Т. В., Жердева Е. И., Малиничева Ю. В., Нестеренко О. И. Артериальная гипертония у больных хронической обструктивной болезнью легких (20-летний опыт изучения) МС. 2012.
Меньшикова Ираида Георгиевна, Магаляс Елена Владимировна, Скляр Ирина Васильевна, Лоскутова Наталья Владимировна Эффективность комплексной терапии при коморбидности артериальной гипертонии и хронической обструктивной болезни легких // Амурский медицинский журнал. 2021. №1. 3→ўзи, янги 3.
Чазова Ирина Евгеньевна, Невзорова Вера Афанасьевна, Амбатьелло Лали Гурамовна, Бродская Татьяна Александровна, Ощепкова Елена Владимировна, Белевский Андрей Станиславович, Жернакова Юлия Валерьевна, Айсанов Заурбек Рамазанович, Овчаренко Светлана Ивановна, Чучалин Александр Григорьевич Клинические рекомендации по диагностике и лечению пациентов с артериальной гипертонией и хронической обструктивной болезнью легких Системные гипертензии. 2020.
Adasheva T.V. Clinical variants of the course and medical correction of arterial hypertension. Dis. ... d-ra med. nauk. Moscow, 2008.
Aksenova TA, Gorbunov VV, Tsarenok SY. Pulse wave velocity and other indicators of arterial stiffness in hypertension comorbidity and chronic obstructive pulmonary disease. Therapeutic Archive 2018; 90 (3): 10–5. 5→52.
Available at: 7→10, [Bolotova E.V., Dudnikova A.V. Peculiarities of renal dysfunction in patients with chronic obstructive pulmonary disease. Klinicheskaya nefrologiya = Clinical Nephrology 2015;(2–3):27–32. (In Russ.)
Balbirsingh V, Mohammed AS, Turner AM, et alCardiovascular disease in chronic obstructive pulmonary disease: a narrative reviewThorax 2022;77:939-945.
Bolotova E.V., Dudnikova A.V. Chronic kidney disease in patients with chronic obstructive pulmonary disease: a role of exacerbations. Russian Pulmonology 2016; 26 (5):578-583 (in Russian).8→3.
Bolotova E.V., Dudnikova A.V. Features of renal dysfunction in patients with chronic obstructive pulmonary disease. Clinical Nephrology 2015; (2-3):27–32 (in Russian).8→1,
Bolotova E.V., Dudnikova A.V. Particular risk factors for chronic kidney disease in patients with chronic obstructive pulmonary disease. Nephrology (SaintPetersburg) 2015; 19(5):28–33 (in Russian).8→2.
Brassington K, Selemidis S, Bozinovski S, Vlahos R. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. Clin Sci (Lond) 2019; 133 (7): 885– 904. 5→50,
Bulcun E., Ekici M., Ekici A., Kisa U. Microalbuminuria in chronic obstructive pulmonary disease. COPD 2013; 10(2):186–192. 8→27.
Chazova I.E., Lazareva N.V., Oshchepkova E.V. Arterial hypertension and chronic obstructive pulmonary disease: clinical characteristics and treatment effectiveness (according to the National Register of Arterial Hypertension. Therapeutic Archive. 2019; 91 (3): 4–10 (in Russian).
Chernyak B.A. Inflammation in chronic obstructive pulmonary disease: clinical significance and the possibilities of pharmacotherapeutic control. Prakticheskaya pulʹmonologiya 2008; 1:23–28 (in Russian). 8→23.
Dolgalev D.V., Ibragimov A.A., Aiypova D.A., Kaliev P.P. Study of microalbuminuria frequency and quantity at chronic obstructive lung disease in conditions of low-hill terrain. Vestnik KRSU 2014; 14(12):96–98 (in Russian).8→7,
Drueke T.B, Parfrey P.S. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012; 82(9):952–960. 8→31.
Fedeli U., De Giorgi A., Gennaro N., Ferroni E., Gallerani M., Mikhailidis D.P., Manfredini R., Fabbian F. Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12:443–450.
Haroun M.K., Jaar B.G., Hoffman S.C., Comstock G.W., Klag M.J., Coresh J. Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington County, Maryland. J. Am. Soc. Nephrol. 2003;14:2934–2941.
Johnston O., Cassidy H., O’Connell S., O’Riordan A., Gallagher W., Maguire P.B., Wynne K., Cagney G., Ryan M.P., Conlon P.J., McMorrow T. Identification of beta-2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods. Proteomics Clin. Appl. 2011; 5(7-8):422–431.8→36.
Kirillova D.A., Tatarsky A.R. The edematous syndrome in patients with chronic obstructive pulmonary disease of lungs: mechanisms of development and approaches to treatment. Rossiyskiy meditsinskiy zhurnal 2017; 23(4):191–196 (in Russian). 8→10.
Kobalava J.D., Bobkova I.N., Villevalde S.V., Efremovtseva M.A., Kozlovskaya L.V., Shvetsov M.Yu., Shestakova M.V. National recommendations. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Russian Journal of Cardiology 2014; 8(112):7– 37 (in Russian).8→11.
Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest 2013; 143 (3): 798–807.5→62.
Mallamaci F. Highlights of the 2015 ERA-EDTA congress: chronic kidney disease, hypertension. Nephrol. Dial. Transplant. 2016; 31(7):1044–1046. 8→39.
Matsumoto T., Murase K., Tachikawa R., Minami T., Hamada S., Tanizawa K., Inouchi M., Handa T., Oga T., Yanagita M., Mishima M., Chin K. Microalbuminuria in patients with obstructive sleep apnea-chronic obstructive pulmonary disease overlap syndrome. Ann. Am. Thorac. Soc. 2016; 13(6):917–925. 8→40.
Miller J, Edwards LD, Aguste A et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE.
Moe Sh.M., Roudebush V.A., Drüeke T.B. Clinical practice guidelines for the diagnosis, evaluation, prevention and treatment of mineral and bone disorders in chronic kidney disease (MKN-CKD). A brief statement by KDIGO. Nefrologiya i dializ = Nephrology and Dialysis 2011;13(1):8–12. (InRuss.).
Muthusami R, Mahmoud M, Crawford E et al. Assessment of chronic obstructive airways disease in heart failure: An analysis of current practice. Am J Respiratory Crit Care Med 2018; 197: 1244. 5→39.
Nagaytseva S.S., Shvetsov M.Yu., Gerasimov A.N., Zhuravleva E.A., Shilov E.M. Assesment of albuminuria as a marker of chronic kidney disease in adult working population. Alʹmanakh klinicheskoy meditsiny 2014; 30:37–45 (in Russiаn).8→16.
Nurgazieva D.S. Chronic kidney disease in patients with chronic obstructive pulmonary disease. Bulletenʹ meditisnskikh Internet-konferentsiy 2016; 6(5):518 (in Russian).8→17.
Ochai H., Uezono S., Kawano H., Ikeda N., Kodama K., Akiyama H. Factors affecting outcome of intracerebral hemorrhage in patients undergoing chronic hemodialysis. Ren. Fail. 2010; 32(8):923–927.8→41.
Oganov R.G., Denisov I.N., Simanenkov V.I. et al. Comorbid pathology in clinical practice. Clinical recommendations. Cardiovascular Therapy and Prevention. 2017; 16 (6): 5–56;
Ovcharenko S.I., Nersesyan Z.N., Morozova T.E. Chronic obstructive pulmonary disease in combination with arterial hypertension: the effectiveness and safety of the use of prolonged-acting indapamide (ArifonR retard). Systemic Hypertension. 2014; 11 (2): 54–8 (in Russian).
Rabahi MF, Pereira SA, Silva Júnior JL et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis 2015;
Rao S, Nazarzadeh M, Li Y, et alSystolic blood pressure, chronic obstructive pulmonary disease and cardiovascular riskHeart 2023;109:1216-1222.
Rydell A, Janson C, Lisspers K, Lin YT, Ärnlöv J. FEV1 and FVC as robust risk factors for cardiovascular disease and mortality: Insights from a large population study. Respir Med. 2024 Jun;227:107614. doi: 10.1016/j.rmed.2024.107614. Epub 2024 Apr 25. PMID: 38670319.
Singanayagam A., Schembri S., Chalmers J.D. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 2013; 10(2):81–89.
SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013; 162 (4): 237–51. 5→49
Vestbo J., Hurd S.S., Agustí A.G., Jones P.W., Vogelmeier C., Anzueto A., Barnes P.J., Fabbri L.M., Martinez F.J., Nishimura M., Stockley R.A., Sin D.D., Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187(4):347–365.8→48.
Wibell L., Evrin P.E., Berggard I. Serum β2 -Microglobulin in Renal Disease. Nephron. 1973; 10(5):320– 331.8→49.
World Health Organization. Noncommunicable diseases country profiles. 2018; Nevzorova V.A., Brodskaya T.A., Martynenko I.M. et al. Prevention of major chronic non-infectious diseases in the structure of mortality. V. 1. Vladivostok: Medicine DV, 2017.
World Health Organization. World report on ageing and health. 2016.
Zadionchenko V.S., Adasheva T.V., Fedorova I.V. et al. Arterial hypertension and chronic obstructive pulmonary disease: clinical and pathogenetic parallels and treatment options. Russian Journal of Cardiology. 2009; 6 (80): 62–8 (in Russian).]5→55.
Zadionchenko V.S., Pogonchenkova I.V., Adasheva T.V. Arterial hypertension and chronic obstructive pulmonary disease. Moscow, 2005 (in Russian).]5→59.
Zakharchuk N, Nevzorova V, Brodskaya T, Gonchar E. Chronic Obstructive Pulmonary Disease and Cardiovascular Comorbidity. J Lung Pulm Respir Res 2018; 5 (1): 00153. 5→15.
